Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke The discovery of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, and programmed cell death ligand 1 (PD-L1) inhibitors, atezolizumab and durvalumab, has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Concurrent radiotherapy (RT) is of particular interest with regard to the potential role for this combination in many settings. The purpose of this commentary is to evaluate the potential for the combination of immune checkpoint inhibitors and radiotherapy, including analysis of studies that have considered this combination in various settings. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/immune-checkpoint-inhibitors-and-radiotherapy-in-nsclc-patients-not-TqWKUB1mfW
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-0092-z
Publisher site
See Article on Publisher Site

Abstract

The discovery of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, and programmed cell death ligand 1 (PD-L1) inhibitors, atezolizumab and durvalumab, has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Concurrent radiotherapy (RT) is of particular interest with regard to the potential role for this combination in many settings. The purpose of this commentary is to evaluate the potential for the combination of immune checkpoint inhibitors and radiotherapy, including analysis of studies that have considered this combination in various settings.

Journal

Oncology and Therapy – Springer Journals

Published: Jan 16, 2019

References

  • Antitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CDS+ T cells
    Dovedi, SJ; Lipowska-Bhalla, G; Beers, SA
  • Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
    Reits, EA; Hodge, JW; Herberts, CA
  • Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells
    Kim, J; Myers, AC; Chen, L
  • Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
    Zhou, Q; Munger, ME; Veenstra, RG
  • The blockade of immune checkpoints in cancer immunotherapy
    Pardoll, DM
  • Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma
    Kalbasi, A; Komar, C; Tooker, GM
  • Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice
    Seifert, L; Werba, G; Tiwari, S
  • Irradiation anf anti-PD-L1 treatment synergistically promote antitumor immunity in mice
    Deng, L; Liang, H; Burnette, B
  • Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
    Demaria, S; Ng, B; Devitt, ML
  • A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger?
    Marconi, R; Strolin, S; Bossi, G
  • Synergistic antitumor activity of tumor-infiltranting lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action
    Cameron, RB; Spiess, PJ; Rosenberg, SA
  • Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation
    Seetharam, S; Staba, MJ; Schumm, LP
  • Combining radiation therapy with interleukine-3 gene immunotherapy
    Chiang, CS; Hong, JH; Wu, YC
  • Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer
    Chakravarty, PK; Alfieri, A; Thomas, EK
  • Combining radiotherapy and immunotherapy: a revived parternship
    Demaria, S; Bhardwaj, N; McBride, WH
  • Immune-mediated inhibition of metastases following treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
    Demaria, S; Kawahima, N; Yang, AM
  • NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
    Heuvel, MM; Verheiji, M; Boshuizen, R
  • Immune checkpoint inhibitor Nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination
    Fiorica, F; Belluomini, L; Stefanelli, A
  • Abscopal responses in metastatic non-small cell lung cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and Ipilimumab: evidence for the in situ vaccination hypothesis of radiation
    Golden, EB; Chachoua, A; Fenton-Kerimian, MB
  • Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell lung cancer
    Pujol, JL; Vansteenkiste, JF; Pas, TM
  • START trial team tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
    Butts, C; Socinski, MA; Mitchell, PL
  • Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model
    Wurz, GT; Gutierrez, AM; Greenberg, BE
  • A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
    Giaccone, G; Bazhenova, LA; Nemunaitis, J
  • START trial team tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
    Butts, C; Socinski, MA; Mitchell, PL
  • Durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer
    Antonia, SJ; Villegas, A; Daniel, D
  • Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC
    Antonia, SJ; Villegas, A; Daniel, D
  • DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab)
    Lin, SH; Lin, Y; Price, J
  • Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14–179
    Durm, GA; Althouse, SK; Sadiq, AA